Adaptimmune Therapeutics plc (ADAP) has risen sharply, recording gains of 6.5% in the past 4 weeks. However, the stock has corrected -0.98% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.07% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.6% and the 50-Day Moving Average is 5.33%.The 200 Day SMA reached 17.41%
Adaptimmune Therapeutics plc (NASDAQ:ADAP): The stock opened in the green at $7.57 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $8.3576 and a low of $7 for the day. The stock did not find buyers even at the lows and closed at $7.05 recording a loss of -1.95%. 854,688 shares exchanged hands during the trading day. The stock had closed at $7.05 in the previous days trading.
Adaptimmune Therapeutics plc (ADAP) : The highest level Adaptimmune Therapeutics plc (ADAP) is projected to reach is $16 for the short term and the lowest estimate is at $10. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $13.67 and the possibility the share price can swing is $3.21.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. The Companys target peptides are NY-ESO-1 and MAGE A-10. The Companys affinity-enhanced TCR therapeutics targets the NY-ESO-1, or NY-ESO, cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate, in patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.